Established and novel disease-modifying treatments in multiple sclerosis.
about
The Therapeutic Potential of the Ketogenic Diet in Treating Progressive Multiple SclerosisAddressing Therapeutic Options for Ebola Virus Infection in Current and Future OutbreaksMultiple Sclerosis and T Lymphocytes: An Entangled StoryCRK proteins selectively regulate T cell migration into inflamed tissues.Regulatory T cells in multiple sclerosis and myasthenia gravis.Improvement of Outcome Measures of Dry Eye by a Novel Integrin Antagonist in the Murine Desiccating Stress Model.Multiple functional therapeutic effects of TnP: A small stable synthetic peptide derived from fish venom in a mouse model of multiple sclerosis.Effects of fumarates on circulating and CNS myeloid cells in multiple sclerosis.Dimethyl fumarate treatment of relapsing-remitting multiple sclerosis influences B-cell subsets.Patient Preferences for Injectable Treatments for Multiple Sclerosis in the United States: A Discrete-Choice Experiment.Patient preferences for treatment of multiple sclerosis with disease-modifying therapies: a discrete choice experiment.Characterization of variations in IL23A and IL23R genes: possible roles in multiple sclerosis and other neuroinflammatory demyelinating diseasesElectroacupuncture Promotes Remyelination after Cuprizone Treatment by Enhancing Myelin Debris Clearance.Opportunities for Translation from the Bench: Therapeutic Intervention of the JAK/STAT Pathway in Neuroinflammatory Diseases.pVAXhsp65 Vaccination Primes for High IL-10 Production and Decreases Experimental Encephalomyelitis Severity.Challenges in randomized controlled trials and emerging multiple sclerosis therapeutics.Current and Emerging Therapies in Multiple Sclerosis: Implications for the Radiologist, Part 1-Mechanisms, Efficacy, and Safety.Reprogramming the Local Lymph Node Microenvironment Promotes Tolerance that Is Systemic and Antigen SpecificAn Autopsy Case of Fulminant Hepatitis in a Patient with Multiple Sclerosis Treated by Interferon-Beta-1a.Salutary effects of glibenclamide during the chronic phase of murine experimental autoimmune encephalomyelitisHumoral response in experimental autoimmune encephalomyelitis targets neural precursor cells in the central nervous system of naive rodents.miR-155 Dysregulation and Therapeutic Intervention in Multiple Sclerosis.Modulating the immune system through nanotechnology.MRI and multiple sclerosis--the evolving role of MRI in the diagnosis and management of MS: the radiologist's perspective.Review of the History of Non-traumatic Spinal Cord Dysfunction.Liposome-based immunotherapy against autoimmune diseases: therapeutic effect on multiple sclerosis."No evidence of disease activity" - is it an appropriate surrogate in multiple sclerosis?[Current aspects of therapy conversion for multiple sclerosis].Rituximab-induced hypogammaglobulinemia in patients with neuromyelitis optica spectrum disordersMultiple sclerosis patients who are stable on interferon therapy show better outcomes when staying on same therapy than patients who switch to another interferon
P2860
Q26769966-8181FF4B-BC08-4E22-9688-F2A9C00EC672Q26801423-C7169E15-B96B-462E-878E-CF541BD45292Q28086853-54D6C356-28C1-406A-AFCC-238A96C2B247Q30628412-69C16711-C7AE-4405-9FEF-E7B35122D206Q33784969-B38295D5-79FE-407F-A924-2D773EF4D1FFQ36050556-4DCB25D6-77AE-4E15-8984-7E4E7AD48DEDQ36290143-66B52C09-5629-47EC-AE95-F8365A2918ACQ36439880-7E0931D8-9BE0-44CC-A041-6022579C5F31Q36669117-6AE95A2E-1692-4773-9666-AAFBEE8DB2A3Q36698871-CA6DACF9-3237-443A-9122-5AAEC471222BQ37301353-B3C7396A-4DA2-428E-8CA9-4AC84083FBD1Q37538191-53663F37-84EA-494F-AD76-360C1DD443B1Q37574779-62A0C386-4759-491C-835F-585CA17D73E3Q37670027-8F447F22-6BB1-4A5F-83F4-4B225C716ABFQ37683473-951E77A1-5337-4DEC-9A7A-0B827E9204C3Q38611027-563687F8-AFD2-4A00-9546-C3731C2BB268Q38837567-D252ED9D-C0E9-4A15-8C2E-AD21B88C38E9Q41101351-00C74B52-1C3C-40CB-94F8-B057D41D333FQ41308066-DE074296-DA87-4FB0-8D58-4DF5F3701258Q41594953-E902716F-B8F8-44C7-9068-E59ED424DB5EQ46408884-A2DA5F8D-5567-48C0-B6D2-F5FD6FC1AF89Q48108346-B8264355-D54A-4465-897E-FDCB89C3AA51Q48630939-A1C9E8D3-E9F4-4879-A8B1-689674D7D9D8Q49606221-65B23293-64FA-40EE-8CF0-F1DEFABE40C1Q50017915-E66DF38F-368B-4FA4-9C3F-8580A1769764Q50953987-DDB4B01D-4B98-4DA9-9F37-F9E067A61D3BQ52567799-42116A61-977D-47E8-A4F9-9976A78DB355Q53582374-A153560D-607F-4D33-A80B-7587735B362AQ58742950-6A544F05-CB5D-47F7-A91D-39A2518E16A1Q59125930-5890210A-4215-4DB6-BE47-4E929304C059
P2860
Established and novel disease-modifying treatments in multiple sclerosis.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Established and novel disease-modifying treatments in multiple sclerosis.
@en
type
label
Established and novel disease-modifying treatments in multiple sclerosis.
@en
prefLabel
Established and novel disease-modifying treatments in multiple sclerosis.
@en
P2860
P356
P1476
Established and novel disease-modifying treatments in multiple sclerosis.
@en
P2093
R T Naismith
P2860
P304
P356
10.1111/JOIM.12203
P407
P577
2014-03-11T00:00:00Z